ArticleClinical and experimental nephrology2025
Association between elevated serum soluble B7-H6 and infection in hemodialysis patients.
Article in Clinical and experimental nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundInfection represents the second most common factor causing death in uremia, partly owing to immune dysfunction. Soluble B7-H6, a soluble form of cell-surface immunoreceptor B7-H6, is induced under infectious conditions. So far, the levels of circulating soluble B7-H6 in uremia cases have not been examined.
methodsIn this prospective cohort study, 55 patients undergoing maintenance hemodialysis were recruited from October 2021 to February 2022; 20 healthy volunteers were enrolled. INTERVENTION(S): None. All hemodialysis cases were followed up until death, switched to peritoneal dialysis, transplantation, or confirmed infection.
resultsPatients were followed up for a mean duration of 331 days. Sixteen hemodialysis cases were diagnosed with infectious diseases, including pneumonia in seven cases, urinary tract infection in four, shingles in two, cutaneous infection in two, and sepsis in one. Compared with healthy controls, serum soluble B7-H6 amounts were markedly elevated in hemodialysis cases with or without infection (P < 0.001). Soluble B7-H6 levels were markedly increased in hemodialysis cases with infection compared to counterparts without infection (P < 0.001). Multivariable Cox proportional hazards model showed that soluble B7-H6 was the significant predictor of infection in hemodialysis patients (hazard ratio 3.308; 95% confidence interval 1.118-9.794; P = 0.031). Patients with high-serum soluble B7-H6 levels had a markedly higher cumulative hazard rate of infection in comparison with the low-serum soluble B7-H6 group (P < 0.05). Finally, soluble B7-H6 levels were positively correlated with neutrophil count (P < 0.05).
conclusionsThis study first showed that serum soluble B7-H6 is elevated in hemodialysis patients and could be considered a potential predictive factor of infection under such conditions.
Indexed as
Identifiers
40425991What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.